Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAMERA 2: Beta-lactam addition to standard therapy for MRSA bacteraemia
NCT02365493Phase 3Terminated
- Sponsor
- Menzies School of Health Research
- Start
- Aug 2015
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of flucloxacillin in Staphylococcus aureus bacteremia (SAB) (2 arms), sponsored by Menzies School of Health Research. Primary endpoint: Complication-free 90-day survival. Started Aug 2015; status: terminated.
02
Drugs
flucloxacillin
03
Conditions
Staphylococcus aureus bacteremia (SAB)
Beyond the preview
Go deeper on NCT02365493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02365493.